Bausch + Lomb Earnings Call Transcripts
Fiscal Year 2026
-
BL 1107, a novel neuroprotective glaucoma therapy, is advancing through phase II with promising early data and strong patent protection, while ELIOS, an implant-free excimer laser MIGS, has shown durable IOP reduction and medication-free rates in pivotal studies. Both assets target significant unmet needs and are expected to drive substantial growth, with ELIOS approval anticipated in 2026.
-
The conference highlighted a robust innovation-driven strategy, with major product launches in consumer, contact lens, pharma, and surgical segments expected through 2029. Margin expansion, double-digit EPS growth, and strong free cash flow are forecast, supported by operational excellence and disciplined capital allocation.
Fiscal Year 2025
-
Record Q4 and full year results featured 7% revenue and 27% adjusted EBITDA growth, with all segments contributing and strong operating leverage. 2026 guidance calls for 5–7% revenue growth and 15% adjusted EBITDA growth, supported by robust product launches, margin expansion, and continued execution.
-
Management outlined a multi-year transformation focused on operational, financial, and innovation excellence, with Vision 27 driving margin and sales growth. Key product launches and a robust pipeline support a 5%-7% revenue CAGR and 600 basis point margin improvement by 2028.
-
Management outlined a strategy for 5%-7% annual revenue growth and a 23% EBITDA margin by 2028, driven by premium product launches, operational efficiencies, and a robust R&D pipeline. Key innovations include a bioactive contact lens, dual-action dry eye therapy, and precision medicine in retina, with regular launches planned through 2032.
-
Q3 2025 saw 6% revenue growth, strong performance across all segments, and robust cash flow. Premium IOLs and pharmaceuticals, especially MIEBO, drove results, while margin expansion and disciplined capital allocation remain priorities.
-
Strong top-line growth, operational improvements, and a robust innovation pipeline are driving performance, with a focus on margin expansion and comprehensive eye care. Key product launches and AI-driven marketing are fueling growth, while Investor Day in November will outline long-term targets.
-
Q2 revenue grew 3% year-over-year, with strong gains in dry eye and contact lens portfolios, despite a major recall and generics headwinds. Full-year guidance was raised, reflecting confidence in recovery, margin expansion, and robust R&D pipeline.
-
Q1 saw 5% overall growth, with strong gains in surgical and lens segments and continued leadership in dry eye. The pipeline is robust, with multiple launches planned and a focus on innovation. Tariff impacts are now expected to be fully offset in 2025, and guidance remains positive for the year.
-
Q1 2025 saw 5% constant currency revenue growth, led by strong vision care and surgical segments, despite a one-time Invista recall impact. Full-year guidance was raised, with robust innovation and mitigation strategies in place for tariff risks.
-
The conference highlighted a strategic transformation with strong global growth, a robust innovation pipeline, and a focus on operational excellence. Key product launches and targeted M&A are set to drive above-market growth, with new clinical trials and launches planned through 2031.
Fiscal Year 2024
-
Double-digit revenue growth continued in Q4 and full-year 2024, driven by innovation, new product launches, and strong execution across all segments. 2025 guidance anticipates 5.5%–7.5% constant currency growth, margin expansion, and positive free cash flow, with investments in R&D and DTC expected to support long-term growth.
-
Revenue grew 19% year-over-year, driven by strong performance in all segments, especially dry eye and contact lenses. Margin expansion continued, with robust product launches and digital investments supporting future growth. Full-year guidance was raised, reflecting ongoing momentum.
-
Delivered 20% constant currency revenue growth with strong performance across all segments and geographies. Raised full-year revenue and EBITDA guidance, driven by successful product launches and continued investment in innovation, despite currency and margin headwinds.